Browse medicines, page 21 of 37

Use listed on the medicine record

VARUBI ® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. ( 1 )

Use listed on the medicine record

XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes. XADAGO is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing "off" episodes ( 1 )

Use listed on the medicine record

Indigestion, heartburn, or abdominal discomfort or bloating

Use listed on the medicine record

Fights and helps prevent recurrence of flaking and itching due to dandruff Use Fights and helps prevent recurrence of flaking and itching associated with dandruff Use Fights and helps prevent recurrence of flaking and itching associated with dandruff Use Fights and helps prevent recurrence of flaking and itching associated with dandruff.

Use listed on the medicine record

Pulmonary arterial hypertension

Use listed on the medicine record

Serum phosphorus

Use listed on the medicine record

Apply the product to the surface of the skin.

Use listed on the medicine record

Diagnostic positron emission tomography (PET) imaging of bone to define areas of altered osteogenic activity

Use listed on the medicine record

PERIKABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PERIKABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients. PERIKABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Use listed on the medicine record

ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ( 1 )

Use listed on the medicine record

The prevention and reversal of bronchospasm

Use listed on the medicine record

Procedures requiring a rapid and short-acting topical ophthalmic anesthetic

Use listed on the medicine record

Trichomoniasis caused by Trichomonas vaginalis

Use listed on the medicine record

The topical field treatment of actinic keratosis on the face or scalp

Use listed on the medicine record

Serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below

Use listed on the medicine record

Metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy

Use listed on the medicine record

Regul Oil Cleansing Cream indications

Use listed on the medicine record

Temporarily relieves pain and itching associated with: • insect bites • minor burns • minor cuts • minor skin irritations • scrapes • sunburn • rashes due to poison ivy, poison oak, or poison sumac

Use listed on the medicine record

Adults and children 12 years of age : apply generously to the affected area, massage into painful area until thoroughly absorbed into the skin, repeat as necessary, but not more than 3 to 4 times daily. Children under 12 years of age : ask a doctor.

Use listed on the medicine record

For mydriasis and cycloplegia for diagnostic procedures.

Use listed on the medicine record

TUKYSA is a kinase inhibitor indicated: • in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ( 1.1 ) • in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Use listed on the medicine record

Anemia due to chronic kidney disease

Use listed on the medicine record

Duchenne muscular dystrophy

Use listed on the medicine record

Unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test

Use listed on the medicine record

Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated

Use listed on the medicine record

Generalized myasthenia gravis

Use listed on the medicine record

INSTRUCTIONS FOR USE 1. Cleanse and moisturize. 2. Apply the mask evenly to the face, avoiding eyes and mouth. 3. Let dry for 15 mins, then sleep. 4. Remove mask or rinse next morning.

Use listed on the medicine record

CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.

Use listed on the medicine record

Presbyopia

Use listed on the medicine record

Severe psoriasis

Use listed on the medicine record

The maintenance treatment of patients with chronic obstructive pulmonary disease

Use listed on the medicine record

The signs and symptoms of dry eye disease

Use listed on the medicine record

The cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis

Use listed on the medicine record

Intravenous adenosine injection, USP is indicated for the following: Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine injection, USP administration. It is important to be sure the adenosine injection, USP solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ).

Use listed on the medicine record

Metastatic squamous NSCLC progressing after platinum-based chemotherapy

Use listed on the medicine record

Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms

Use listed on the medicine record

INDICATIONS& USAGE Suitable for all types of skin damage due to stretching of the skin. Apply all over skin, concentrating on tummy, hips, thighs and bust.Massage liberally into skin twice daily.